Table S2.
Age at necrosis
| Treatment group | Facial vein (μg/g) | Mean age at necrosis ± SD (d) | ||||
| PND0 | PND2 | Tail | Ear | Nose | Feet | |
| Single administration | ||||||
| Untreated | NA | NA | NA | NA | ||
| PMO | 10 | NA | NA | NA | NA | |
| Pip6a-PMO scrambled | 10 | NA | NA | NA | NA | |
| Pip6a-PMO | 2.5 | 47 ± 3.8 | 49 ± 5.5 | 59 ± 0.0 | 75 ± 18.4 | |
| Pip6a-PMO | 5 | 49 ± 6.5 | 41 ± 4.9 | 70 ± 7.1 | 111 ± 22.5 | |
| Pip6a-PMO | 10 | 70 ± 9.7 | 47 ± 10 | 71 ± 11 | 193 ± 54.0 | |
| Double administration | ||||||
| PMO | 10 | 10 | 49 (n = 1) | 50 (n = 1) | ||
| Pip6a-PMO scrambled | 10 | 10 | NA | NA | NA | NA |
| Pip6a-PMO | 5 | 5 | 65 ± 11.8 | 50 ± 5.7 | 84 ± 21.4 | 175 (n = 1) |
| Pip6a-PMO | 10 | 10 | 67 ± 0.0 | 55 ± 6.7 | 104 ± 14.8 | 296 ± 67.3 |
NA, not applicable.